Science 37 Holdings (Science 37 Holdings) Cash Flow from Financing : $-0.22 Mil (TTM As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Science 37 Holdings Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Sep. 2023, Science 37 Holdings paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Science 37 Holdings spent $0.00 Mil on financial activities for the three months ended in Sep. 2023.

Science 37 Holdings Cash Flow from Financing Historical Data

The historical data trend for Science 37 Holdings's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Science 37 Holdings Cash Flow from Financing Chart

Science 37 Holdings Annual Data

Trend

Jun20

Jun21

Dec22

Cash Flow from Financing

81.06

0.61

Science 37 Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash Flow from Financing	Get a 7-Day Free Trial									0.20	-0.06	0.09	-	-0.24

Science 37 Holdings Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Science 37 Holdings's Cash from Financing for the fiscal year that ended in Dec. 2022 is calculated as:

	Cash Flow from Financing		(A: Dec. 2022 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	0	+	0	+	0	+	0
=	0.00

Science 37 Holdings's Cash from Financing for the quarter that ended in Sep. 2023 is:

	Cash Flow from Financing		(Q: Sep. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	0	+	0	+	0	+	0
=	0.00

Cash Flow from Financing for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.22 Mil.

Science 37 Holdings (NAS:SNCE) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Science 37 Holdings's issuance of stock for the three months ended in Sep. 2023 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Science 37 Holdings's repurchase of stock for the three months ended in Sep. 2023 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Science 37 Holdings's net issuance of debt for the three months ended in Sep. 2023 was $0.00 Mil. Science 37 Holdings received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Science 37 Holdings's net issuance of preferred for the three months ended in Sep. 2023 was $0.00 Mil. Science 37 Holdings paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Science 37 Holdings's cash flow for dividends for the three months ended in Sep. 2023 was $0.00 Mil. Science 37 Holdings received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Science 37 Holdings's other financing for the three months ended in Sep. 2023 was $0.00 Mil. Science 37 Holdings received $0.00 Mil on other financial activities.

Science 37 Holdings Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Science 37 Holdings's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Science 37 Holdings (Science 37 Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Science 37 Holdings Inc (NAS:SNCE) » Definitions » Cash Flow from Financing

Comparable Companies

Traded in Other Exchanges

N/A

Address

800 Park Offices Drive, Suite 3606, Research Triangle Park, Durham, NC, USA, 27709

Website

https://www.science37.com

Science 37 Holdings Inc is engaged in the development of new and innovative treatments that impact patient lives. It enables universal access to patients and providers for clinical trials. Its Operating System is fused with networks of telemedicine investigators, mobile nurses, remote coordinators, patient communities and connected devices.

Executives

Troy Bryenton	officer: Chief Technology Officer	800 PARK OFFICES DRIVE, SUITE 3606, RESEARCH TRIANGLE PARK NC 27709
Christine A Pellizzari	officer: Chief Legal Officer	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Autenried Paul Von	director	BRISTOL-MYERS SQUIBB COMPANY, 100 NASSAU PARK BOULEVARD, PRINCETON NJ 08543
Michael Shipton	officer: Chief Commercial Officer	800 PARK OFFICES DRIVE SUITE 3606, RESEARCH TRIANGLE PARK NC 27709
Adam Goulburn	director	C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Thermo Fisher Scientific Powder Us Holdings Corp.	10 percent owner	168 THIRD AVENUE, WALTHAM MA 02451
Thermo Fisher Scientific Inc.	10 percent owner	168 THIRD AVENUE, WALTHAM MA 02451
Neil Tiwari	director	C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Darcy Forman	officer: Chief Delivery Officer	C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
David Coman	director, officer: Chief Executive Officer	C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Jonathan Cotliar	officer: Chief Medical Officer	C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Steven Geffon	officer: Chief Commercial Officer	C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
De Silva Bhooshitha B.	director	PPD, INC., 929 NORTH FRONT STREET, WILMINGTON NC 28401
Mike Zaranek	officer: Chief Financial Officer	C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Ppd, Inc.	10 percent owner	929 NORTH FRONT STREET, WILMINGTON NC 28401-3331